XEMBIFY plus usual care to prevent infections
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have one of these diagnoses: B-cell chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or B-cell non-Hodgkin lymphoma (NHL) at the required stage
- Have low IgG antibody levels (specific test rules apply for MM)
- Have had at least 1 severe infection in the past year or at least 3 infections in the past year
- Be well enough to join the study (about 1.5 years or more life expectancy, and no other major problems that could stop participation)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether people with certain blood cancers can safely stop their immune support medicine (immunoglobulin, also called Ig) or whether they should continue. It also tests antibiotic prevention strategies to reduce the risk of serious infections.
This trial tests if a medicine called IgPro20 can help prevent infections in people with multiple myeloma who have low antibody levels and are being treated with a bispecific antibody. If you have relapsed or refractory myeloma and have recently started a bispecific antibody, this study might help protect you from getting serious infections.
This study tests whether a new immune therapy called XEMBIFY works as well as a standard treatment (Gamunex-C) for CIDP, a condition where the immune system damages nerves and causes weakness. Both are given as infusions under the skin every three weeks.
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
This study tests a new immunoglobulin (antibody) treatment called IgPro20 in adults whose immune systems became weakened after receiving CAR-T cell or TCE therapies for blood cancers. The goal is to help strengthen your immune system and reduce infection risk.
This trial compares two treatments—antibiotics or immunoglobulin (a blood product with infection-fighting antibodies)—to see which better prevents infections in people with certain blood cancers like CLL, multiple myeloma, or non-Hodgkin's lymphoma.
Hear when a new Hypogammaglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.